JPWO2020163962A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163962A5 JPWO2020163962A5 JP2021547401A JP2021547401A JPWO2020163962A5 JP WO2020163962 A5 JPWO2020163962 A5 JP WO2020163962A5 JP 2021547401 A JP2021547401 A JP 2021547401A JP 2021547401 A JP2021547401 A JP 2021547401A JP WO2020163962 A5 JPWO2020163962 A5 JP WO2020163962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- pharmaceutical composition
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 6
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000051981 human FCMR Human genes 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806237P | 2019-02-15 | 2019-02-15 | |
| US62/806,237 | 2019-02-15 | ||
| PCT/CA2020/050195 WO2020163962A1 (en) | 2019-02-15 | 2020-02-14 | Fcmr-binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520817A JP2022520817A (ja) | 2022-04-01 |
| JPWO2020163962A5 true JPWO2020163962A5 (enExample) | 2023-02-21 |
Family
ID=72043773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547401A Pending JP2022520817A (ja) | 2019-02-15 | 2020-02-14 | Ｆｃｍｒ結合分子およびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12286476B2 (enExample) |
| EP (1) | EP3924388A4 (enExample) |
| JP (1) | JP2022520817A (enExample) |
| KR (1) | KR20210139273A (enExample) |
| CN (1) | CN113993895A (enExample) |
| AU (1) | AU2020222408A1 (enExample) |
| BR (1) | BR112021016102A2 (enExample) |
| CA (1) | CA3130225A1 (enExample) |
| EA (1) | EA202192254A1 (enExample) |
| IL (1) | IL285585A (enExample) |
| MX (1) | MX2021009767A (enExample) |
| SG (1) | SG11202108837WA (enExample) |
| TW (1) | TWI857009B (enExample) |
| WO (1) | WO2020163962A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009767A (es) | 2019-02-15 | 2021-11-17 | Univ Health Network | Moleculas de union de fmcr y usos de las mismas. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| JP6200437B2 (ja) | 2012-03-16 | 2017-09-20 | ユニバーシティ ヘルス ネットワーク | Ｔｏｓｏ活性を調節するための方法および組成物 |
| AU2014244444A1 (en) * | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
| AU2014286869A1 (en) * | 2013-07-03 | 2016-02-11 | University Health Network | Antibodies to Toso |
| US20150252434A1 (en) * | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| JP6877350B2 (ja) | 2014-11-05 | 2021-05-26 | ジェネンテック， インコーポレイテッド | 抗ｆｇｆｒ２／３抗体及びその使用方法 |
| EP3256163A4 (en) | 2015-02-11 | 2018-10-10 | University Health Network | Methods and compositions for modulating lilr proteins |
| EP3098237B1 (en) * | 2015-05-28 | 2018-08-01 | Universität Zu Köln | Anti-toso chimeric antigen receptor and its use |
| EP3559042A4 (en) | 2016-12-22 | 2020-11-25 | Icahn School of Medicine at Mount Sinai | ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF |
| MX2021009767A (es) | 2019-02-15 | 2021-11-17 | Univ Health Network | Moleculas de union de fmcr y usos de las mismas. |
-
2020
- 2020-02-14 MX MX2021009767A patent/MX2021009767A/es unknown
- 2020-02-14 WO PCT/CA2020/050195 patent/WO2020163962A1/en not_active Ceased
- 2020-02-14 KR KR1020217029786A patent/KR20210139273A/ko active Pending
- 2020-02-14 EP EP20756467.5A patent/EP3924388A4/en active Pending
- 2020-02-14 CA CA3130225A patent/CA3130225A1/en active Pending
- 2020-02-14 US US17/430,311 patent/US12286476B2/en active Active
- 2020-02-14 AU AU2020222408A patent/AU2020222408A1/en active Pending
- 2020-02-14 CN CN202080025378.0A patent/CN113993895A/zh active Pending
- 2020-02-14 SG SG11202108837WA patent/SG11202108837WA/en unknown
- 2020-02-14 EA EA202192254A patent/EA202192254A1/ru unknown
- 2020-02-14 BR BR112021016102A patent/BR112021016102A2/pt unknown
- 2020-02-14 JP JP2021547401A patent/JP2022520817A/ja active Pending
- 2020-02-14 TW TW109104713A patent/TWI857009B/zh active
-
2021
- 2021-08-12 IL IL285585A patent/IL285585A/en unknown